AdvisorShares Psychedelics ETF
AdvisorShares Psychedelics ETF reported 25 holdings worth US$44.4M as of Jun 30, 2026 (Form N-PORT)
As of Jun 30, 2026 · Filed Aug 21, 2026
AdvisorShares Psychedelics ETF reported 25 holdings worth US$44.4M as of Jun 30, 2026. Largest: Definium Therapeutics, Inc., Ataibeckley Inc. and Relmada Therapeutics, Inc. Filed Aug 21, 2026 (Form N-PORT).
- Holdings
- 25
- Value as reported
- US$44.4M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Definium Therapeutics, Inc. | 121K | US$5.71M | 12.9% |
| Ataibeckley Inc. | 883K | US$4.65M | 10.5% |
| Relmada Therapeutics, Inc. | 439K | US$3.04M | 6.8% |
| Nrx Pharmaceuticals, Inc. | 659K | US$2.7M | 6.1% |
| Neurocrine Biosciences, Inc. | 11,553 | US$1.95M | 4.4% |
| Cybin, Inc. | 293K | US$1.93M | 4.4% |
| Gh Research Plc | 71,267 | US$1.92M | 4.3% |
| Alkermes Plc | 36,438 | US$1.91M | 4.3% |
| Alto Neuroscience, Inc. | 70,748 | US$1.87M | 4.2% |
| Abbvie Inc. | 7,318 | US$1.84M | 4.1% |
| Bright Minds Biosciences Inc. | 24,274 | US$1.7M | 3.8% |
| Johnson & Johnson | 6,308 | US$1.6M | 3.6% |
| Supernus Pharmaceuticals, Inc. | 27,618 | US$1.28M | 2.9% |
| Neuphoria Therapeutics Inc. | 253K | US$1.11M | 2.5% |
| Neuronetics, Inc. | 743K | US$966K | 2.2% |
| Quantum Biopharma Ltd. Subordinate Voting Shares Class B | 204K | US$737K | 1.7% |
| Optimi Health Corp. | 103K | US$523K | 1.2% |
| Pasithea Therapeutics Corp. | 938K | US$483K | 1.1% |
| Psyence Biomedical Ltd. | 122K | US$374K | 0.84% |
| Incannex Healthcare Inc. | 60,868 | US$229K | 0.52% |
| Igc Pharma, Inc. | 678K | US$185K | 0.42% |
| Vistagen Therapeutics, Inc. | 439K | US$99,133 | 0.22% |
| Enveric Biosciences, Inc. | 35,417 | US$48,875 | 0.11% |
| Clearmind Medicine Inc. | 1,169 | US$2,572 | <0.01% |
| Silo Pharma, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related